康华生物：公司高度重视疫苗业务的国际化布局

Group 1 - The company emphasizes the importance of internationalization in its vaccine business and is actively pursuing overseas strategies [1] - The company has achieved a significant milestone with its six-valent norovirus vaccine, having signed a licensing agreement that resulted in an upfront payment of 15 million USD [1] - The ACYW135 group meningococcal polysaccharide vaccine has successfully been exported, with further operational results to be disclosed in the company's regular reports [1]